• Home
  • About Us
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Terms & Conditions
Wednesday, February 1, 2023
Flyy News
No Result
View All Result
  • Home
  • World
  • Business
  • Entertainment
  • Health
  • Food
  • Politics
  • Tech
  • Science
  • Travel
  • Fashion
  • Lifestyle
  • Home
  • World
  • Business
  • Entertainment
  • Health
  • Food
  • Politics
  • Tech
  • Science
  • Travel
  • Fashion
  • Lifestyle
No Result
View All Result
Flyy News
No Result
View All Result
Home Health

Scientists are hopeful that Paxlovid may help guard against long COVID : Shots

flyynews by flyynews
November 9, 2022
in Health
0
Scientists are hopeful that Paxlovid may help guard against long COVID : Shots
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter


Patients had a reduced risk of developing long COVID after taking Paxlovid, and the benefits were seen among those who were vaccinated and unvaccinated.

Stephanie Nano/AP


hide caption

toggle caption

Stephanie Nano/AP


Patients had a reduced risk of developing long COVID after taking Paxlovid, and the benefits were seen among those who were vaccinated and unvaccinated.

Stephanie Nano/AP

It’s well-documented that Paxlovid — a 5-day course of antiviral pills from Pfizer — can reduce the risk of hospitalization in COVID-19 patients who are more likely to develop severe illness.

Now, researchers from the Veterans Health Administration find that taking the medication may also reduce the risks of later developing long COVID, according to a new study that was posted online this weekend and has not yet undergone peer review.

“We’ve already known for some time now that Paxlovid reduces the risk of acute problems,” says Dr. Ziyad Al-Aly, chief of research and development at the VA Saint Louis Healthcare System, and co-author of the study, “Now we are adding the observation that Paxlovid also reduces the risk of long COVID.”

The drug, which has been available in the U.S. for almost a year, is provided for free by the federal government at pharmacies across the country. It requires a prescription, and patients with COVID-19 must start it within five days of symptom onset.

Less virus, less long COVID?

In the study, long COVID was defined as developing one or more symptoms — including heart issues, blood disorders, fatigue and trouble breathing — one to three months after testing positive. By these metrics, patients that took Paxlovid were 26% less likely to develop long COVID.

To get to this finding, the researchers combed through electronic health records from more than 56,000 patients in the VA health system who tested positive for COVID-19 between March and June 2022, and had at least one risk factor for severe disease. They compared health outcomes of 9,000 patients that had taken Paxlovid early in their course of illness, with 47,000 patients that had not.

The benefits of taking Paxlovid didn’t just apply to those who were unvaccinated. Patients who were vaccinated or boosted, or had repeat COVID-19 infections, had a similar reduction in the risk of developing long COVID, the study found.

The study is a preprint, meaning it was shared publicly before being reviewed and vetted by outside researchers. But experts who were not involved in the study tell NPR the findings make sense, given how Paxlovid works.

The antiviral drug stops the virus from replicating in cells. “We know that one of the key factors that predict long COVID is detectable virus in the bloodstream at the time of infection,” Dr. Peter Chin-Hong, an infectious disease physician at the University of California, San Francisco, wrote in an email. “So it stands to reason that interventions that prevent the virus from making more copies of itself would therefore lead to a lower risk of long COVID.”

Past studies have shown that Paxlovid reduces the risks of hospitalization and death from COVID-19. “Since the trigger of long COVID is acute infection with SARS-CoV-2, it makes intuitive sense that anything that lowers the severity of this infection would reduce the risk of long COVID, whether it’s Paxlovid or other antiviral treatments,” Dr. Paul Sax, an infectious disease physician at Brigham and Women’s Hospital in Boston, wrote in an email.

A starting point

Still, experts view the study as only a starting point for exploring the potential uses of Paxlovid. The VA study was observational, based on data entered into patient health records – in Sax’s view, “the imprecision of the [long COVID] diagnosis makes definitive conclusions from this study challenging, especially with a retrospective review.”

But the value of the study is that it points researchers down promising pathways for more research, says Dr. Monica Gandhi, an infectious disease physician at UCSF. “It’s hypothesis-generating,” she says, “It’s exciting and hopeful [to think] that if you reduce the viral load… down to undetectable [early in the illness], maybe you can prevent post-COVID symptoms” altogether – a theory she thinks researchers could pursue.

Both Sax and Gandhi say they would feel more confident in the results if they were replicated in additional studies, especially in experimental, randomized controlled trials that compare long COVID outcomes in patients who took either Paxlovid or a placebo. The VA study’s findings are also limited by the fact that the participants were predominantly white men, raising the possibility that the benefits of Paxlovid could be different in other groups of patients.

Currently, Paxlovid is only authorized for use in patients who have risk factors – like being older or having underlying health conditions – that put them at high risk of developing severe disease. Al-Aly says the reduction in long COVID risk, raised in his study, suggests others might benefit from taking Paxlovid, too. But many patients who currently have long COVID were relatively young and healthy before they got COVID-19 and may not have qualified for Paxlovid when they tested positive, he says.

“Does Paxlovid use in a lower-risk population reduce the risk of acute problems and subsequently reduce the risk of long COVID?” Al-Aly wonders, “I think that’s a question that we all need to solve over the next several months.”

It’s also an open question whether a higher dose or a longer treatment course could provide a greater benefit, Chin-Hong says.

Side effects that include nausea and an off-putting taste have given patients pause about using the product. Reports of COVID rebound in Paxlovid patients, where the illness flares up after a seeming respite, has made some prescribers ambivalent about the product. These are real considerations, Al-Aly says, but they should be weighed against the benefits of Paxlovid treatment, including reduced risks of hospitalization and death in the acute phase, and the potential for avoiding long COVID in the months after.

Gandhi says the study’s findings may now factor into clinicians’ decisions, even if the results are preliminary and have not yet been replicated.

“This study is pushing me to use [Paxlovid] in people who are over 65, vaccinated and boosted, because it’s probably going to have other benefits beyond preventing hospitalization,” she says.



Source_link

READ ALSO

Lunit’s AI boosts Guardant Health’s cancer detection capability

What is Cryotherapy? | Mark’s Daily Apple

Related Posts

Lunit’s AI boosts Guardant Health’s cancer detection capability
Health

Lunit’s AI boosts Guardant Health’s cancer detection capability

February 1, 2023
What is Cryotherapy? | Mark’s Daily Apple
Health

What is Cryotherapy? | Mark’s Daily Apple

February 1, 2023
The Deep Health Coaching Method from Precision Nutrition
Health

The Deep Health Coaching Method from Precision Nutrition

January 31, 2023
U.S. Parents Face Big Disparities in Access to Autism Care Services
Health

U.S. Parents Face Big Disparities in Access to Autism Care Services

January 31, 2023
Biden to End COVID-19 National Emergencies on May 11
Health

Biden to End COVID-19 National Emergencies on May 11

January 31, 2023
Neurosurgeon Henry Marsh reflects on life and death as a cancer patient : Shots
Health

Neurosurgeon Henry Marsh reflects on life and death as a cancer patient : Shots

January 30, 2023
Next Post
Paytm share price: Hot Stocks: Global brokerages on Cummins India, Paytm, and Jubilant FoodWorks post Q2 results

Paytm share price: Hot Stocks: Global brokerages on Cummins India, Paytm, and Jubilant FoodWorks post Q2 results

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

POPULAR NEWS

Angel -Dave Curl – Official Music Video 2022

Angel -Dave Curl – Official Music Video 2022

November 17, 2022
Proud By Cytonic Rhymes – Official Music 2022

Proud By Cytonic Rhymes – Official Music 2022

November 25, 2022
Sweet Bennie Ray – Whole Lot (Official Music Video)

Sweet Bennie Ray – Whole Lot (Official Music Video)

December 22, 2022
SUPER VITAMIN C COLLECTION | STRIVECTIN

SUPER VITAMIN C COLLECTION | STRIVECTIN

December 16, 2022
Rain And Lily Pond Sounds | 10 Hours | Sleep, Relaxation | Dark Screen

Rain And Lily Pond Sounds | 10 Hours | Sleep, Relaxation | Dark Screen

November 14, 2022

About Us

Welcome to Flyy News The goal of Flyy News is to give you the absolute best news sources for any topic! Our topics are carefully curated and constantly updated as we know the web moves fast so we try to as well.

Follow us

Categories

  • Business
  • Entertainment
  • Fashion
  • Food
  • Gaming
  • Health
  • Lifestyle
  • Politics
  • Reviews
  • Science
  • Tech
  • Travel
  • World

Site Links

  • Home
  • About Us
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Terms & Conditions

Recent News

  • Easy Baked Chicken Breasts (Juicy and Tender!)
  • Corsair PSUs with side-mounted power connectors are now available
  • Polish leader donates to Ukraine army to end defamation case
  • Chris Wallace Has Worst Ratings Month Since Launch Of CNN Show

Copyright © 2022 Flyynews.com | All Rights Reserved.

No Result
View All Result
  • Home
  • World
  • Business
  • Entertainment
  • Health
  • Food
  • Politics
  • Tech
  • Science
  • Travel
  • Fashion
  • Lifestyle

Copyright © 2022 Flyynews.com | All Rights Reserved.

What Are Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT